Description
Cabazitaxel is a semi-synthetic taxoid that is an effective antineoplastic agent used in the treatment of prostate cancer and breast cancer. Cabazitaxel is shown to disrupt the microtubular network in cells that exhibit P-glycoprotein (Pgp) mediated drug resistance. Its poor affinity for Pgp makes it a more effective therapeutic agent than docetaxel in cancer cells that become resistant to the taxane class of cancer drugs.